Agios Pharmaceuticals Inc (NASDAQ:AGIO), a leader in the fields of cancer metabolism and rare genetic disorders of metabolism, announced that new clinical and preclinical data from the company’s lead programs will be presented at the 20th Congress of the European Hematology Association (EHA) taking place June 11-14, 2015 in Vienna. Agios’ cancer metabolism medicines are being developed in collaboration with Celgene.
“EHA is an important meeting for us this year as we share new and encouraging data for each of our three lead clinical programs,” said Chris Bowden, M.D., chief medical officer of Agios. “Data from the ongoing Phase 1 studies of our mutant-IDH inhibitors in hematologic malignancies support the continued development of these molecules as we move into global registration programs. In addition, complete findings from our MAD study of AG-348, coupled with the natural history study of PK deficiency from Boston Children’s Hospital, inform our understanding of the disorder and dosing as we prepare to initiate a Phase 2 study in patients in the coming weeks.”
Highlights of selected data presentations include:
AG-221: a first-in-class, oral, selective, potent inhibitor of the mutated IDH2 protein
- A poster presentation will provide new safety and efficacy data from the ongoing Phase 1 study of AG-221 in advanced IDH2-mutant hematologic malignancies, including longer follow-up data, additional patients and early molecular data from the Phase 1 dose escalation study, in addition to initial data from the expansion cohorts initiated in October 2014.
AG-120: a first-in-class, orally available, selective, potent inhibitor of the mutated IDH1 protein
- A poster presentation will provide new safety and efficacy data from the ongoing Phase 1 study of AG-120 in advanced IDH1-mutant hematologic malignancies, including longer follow-up data and additional patients since the initial data presentation in November 2014 at the 26th Annual EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
AG-348: a novel, first-in-class, oral activator of pyruvate kinase-R (PKR) for the treatment of pyruvate kinase (PK) deficiency
- An oral presentation for AG-348 will include the final data showing safety, tolerability, pharmacokinetic data and effects on pharmacodynamics markers from the multiple ascending dose escalation (MAD) study in healthy volunteers.
- A poster presentation and an e-poster from Boston Children’s Hospital will show the first data from a natural history study of PK deficiency. (Original Source)
Shares of Agios closed yesterday at $116.88 . AGIO has a 1-year high of $138.85 and a 1-year low of $31.51. The stock’s 50-day moving average is $103.03 and its 200-day moving average is $106.25.
On the ratings front, Agios has been the subject of a number of recent research reports. In a report issued on May 8, MLV & Co. analyst Arlinda Lee maintained a Buy rating on AGIO, with a price target of $130, which represents a potential upside of 11.2% from where the stock is currently trading. Separately, on May 7, Canaccord Genuity’s John Newman maintained a Hold rating on the stock and has a price target of $103.
According to TipRanks.com, which ranks over 7,500 financial analysts and bloggers to gauge the performance of their past recommendations, Arlinda Lee and John Newman have a total average return of -0.3% and 8.1% respectively. Lee has a success rate of 53.8% and is ranked #2762 out of 3607 analysts, while Newman has a success rate of 56.5% and is ranked #606.
Agios Pharmaceuticals Inc is engaged in the development of medicines to treat cancer metabolism and inborn errors of metabolism, which are a subset of orphan genetic metabolic diseases.